Prominent diseases of the endocrine system, such as diabetes mellitus, hypogonadism, and hyperprolactinemia, may cause erectile dysfunction (ED). ED affects about 50% of male diabetic patients possibly due to the vascular and neuropathic complications. Metabolic control and selective phosphodiesterase type 5 inhibitors are therapies of choice for controlling ED. By correcting hypogonadism, testosterone levels are restored. This, and the use of dopaminergic drugs, which normalize prolactin levels in male hyperprolactinemia, may be effective in reversing ED in these endocrine disorders.
Introduction
Erectile dysfunction (ED) is a disorder with multiple etiologies, which may be psychogenic and/or organic in origin. Among the organic causes of ED are diseases of the endocrine system, including diabetes mellitus, hypogonadism, and hyperprolactinemia. ED may also occur with other endocrine diseases, such as severe hypothyroidism (less frequent in thyrotoxicosis) and adrenal insufficiency, although these are secondary causes and have little relevance in clinical context. Finally, there are anecdotal cases of an endocrine-metabolic origin, such as iatrogenic or organic elevation of estrogens, malnutrition, and anorexia and bulimia nervosa.
Diabetes mellitus
Unquestionably, patients with diabetes have the highest prevalence of ED, compared with the other endocrine disorders. Although reports of the exact prevalence are conflicting, most studies indicate that it affects about 50% of diabetic patients. 1 The pathogenesis of ED involves diabetic microvascular complications, such as neuropathy of the autonomous nervous system and vasculopathy. From a pathophysiological point of view, a deficiency of nitric oxide (NO) occurs due to its decreased production by NO synthase in advanced diabetes mellitus 2, 3 and to its inactivation by free radicals and advanced glycation endproducts. 4 The deficiency of NO contributes to ED directly by its vascular effects and indirectly by favoring the development of autonomic neuropathy. 5 
Hypo-and hypergonadotropic hypogonadism
Androgen deficiency is accompanied by a reduction of sexual desire and nocturnal tumescence, both signs of reduced sexual function. 6 Many studies stress that a gradual decrease in androgen levels, such as testosterone, dehydroepiandrosterone (DHEA), and dehydroepiandrosterone sulfate (DHEAS), occurs with advanced age (from the fifth decade of life). 7, 8 Increased levels of sex hormonebinding globulin (SHBG) and a disproportional increase in gonadotropins may further contribute to a relative deficiency of these hormones. Although hypogonadism may not occur during senescence, blood testosterone levels in some elderly persons reach the hypogonadal range and the administration of testosterone when concentrations are below 200-300 ng/ml is currently being tested. 8, 9 To date, trials with intramuscular or transdermal testosterone have been shown to promote an increase in sexual desire, sexual potency, nocturnal tumescence of the penis, and a feeling of well being in patients. 8 Likewise, results from various studies indicate that sildenafil is an effective and well-tolerated treatment for ED in aging men. 10 
Hyperprolactinemia
Hyperprolactinemia often occurs secondary to drugs with antidopaminergic effects, particularly tricyclic antidepressants or gastrointestinal prokinetic agents, such as metoclopramide.
11 When hyperprolactinemia is caused by a pituitary tumor, it can present as a macroadenoma, because diagnosis is frequently delayed in male patients. Hyperprolactinemia leads to ED at the level of the brain's dopaminergic system and also due to testosterone deficiency secondary to the inhibition of the pulsatile secretion of gonadotropin-releasing hormone (GnRH).
12,13
Other diseases ED only occurs with thyroid and adrenal disease when these conditions are in advanced stages due to mechanisms yet to be determined. Hypofunction of Leydig cells has been noted in hypercortisolism; circulatory disorders that occur in Addison's disease and in thyroid dysfunctions may contribute to ED. 14 Other diseases that may have secondary gonadal impact and cause ED are severe malnutrition (in which GnRH secretion is inhibited by increased dopaminergic and opioid activity in the hypothalamus), and advanced chronic renal or hepatic failure. Liver disease causes a decrease in sexual desire and ED, as well as the appearance of feminine secondary sexual characteristics such as gynecomastia. This is attributed to increased aromatization of androgens to estrogens, higher SHBG levels (which reduce free testosterone), and possibly to an associated primary testicular failure. ED has been attributed to similar mechanisms in chronic renal failure, 15 and, owing to a defect of metabolic clearance of this hormone, may be associated with moderate hyperprolactinemia.
Diagnostic/therapeutic proposal
Only the most relevant diseases will be discussed from a clinical practice point of view:
Diabetes mellitus. Plasma glucose levels must exceed 126 mg/dl in a fasting state or 200 mg/dl at any time of the day, and must be measured on at least two separate occasions for a diagnosis of diabetes. Effective treatment consists of correcting and maintaining metabolic control for diabetes. For men with ED, treatment with oral phosphodiesterase type 5 inhibitors is recommended. Sildenafil has been well characterized in diabetic patients, with success rates of 56-67% in this population, compared with 10-29% with placebo. [16] [17] [18] For most patients the doses are 25, 50 or 100 mg 1 h before intercourse, and can be taken only once daily. Sildenafil has no effect in the absence of sexual stimulation, and is contraindicated in patients who are taking nitrates for cardiovascular disease. 19 Other treatment options for ED include tadalafil and vardenafil. [20] [21] [22] [23] Apomorphine, 24 and more recently, an alpha-melanocyte-stimulating hormone analogue, act on the central nervous system, yet have not been adequately studied in patients with diabetes mellitus. Nausea is a disabling side effect in these drugs. 25 If these first-line treatments fail, there are several second-and third-line treatment options, which are described in more detail in the core document. Second-line treatments include alprostadil (not marketed in Spain), which is administered intraurethrally at a dose of 250-1000 mg or injected into the corpora cavernosa at doses of 5-20 mg, and has achieved acceptable results in diabetics. 26 Hypogonadism. Screening for hypogonadism, in addition to a thorough medical history and physical examination, should include total or, preferably, free plasma testosterone levels to make the appropriate corrections for the age of the patient. Treatment with testosterone (intramuscularly as testosterone enanthate or cypionate at a dose of 150-250 mg/15-20 days, or nonscrotal transdermally at a daily dose of 2.5-5 mg) corrects androgen deficiency and the resulting symptoms. Digital rectal examination and determination of prostate markers should be performed regularly in treated patients. Therapeutic correction of hypogonadism almost always improves sexual desire and potency in patients who have ED as a result of this disease. 27, 28 Hyperprolactinemia. Hyperprolactinemia is often caused by sulpiride and other antidepressants. 11 If the causative drug is withdrawn, hyperprolactinemia disappears and consequently the resulting clinical manifestations. In the case of primary hyperprolactinemia, the diagnosis is confirmed by elevation of prolactin levels in laboratory tests. Normal prolactin levels can be restored by treatment with cabergoline (0.25-2 mg/week) or quinagolide (75 mg/day). 
